Uterine Fibroid Treatment Market: Improving Quality of Life in Childbearing Women

Uterine fibroids are a common non-cancerous type of tumor that can appear in and on the uterus. Also referred to as leiomyomas, uterine fibroids are made up of muscle and fibrous tissue and usually occur in women aged 30 to 50. Fibroids often don’t have any symptoms but may result in heavy bleeding, pain, and discomfort in some women.

Treatment for uterine fibroids may take the form of medication, homo therapy, or surgery. In this blog post, we take a look at the different types of uterine fibroids and the symptoms associated with them. Also, we cover the current industry scenario and major factors fueling the uterine fibroid treatment market growth. Read on!

Types of Uterine Fibroids

Uterine fibroids can be categorized into several different types. Here are some specific types of uterine fibroids:

Intramural fibroids: #Intramural_fibroids can grow into the uterus’ muscular wall. The size of intramural fibroids can range between 1 mm to 20 cm.

Submucosal fibroids: These fibroids grow just under the inner lining of the uterus. #Submucosal_fibroids can develop individually or appear in the form of clusters.

Subserosal fibroids: Subserosal fibroids grow on the outside of the uterus. In unusual cases, these fibroids can get large and grow into the pelvis.

Pedunculated fibroids: This fibroid type attaches to the wall of the uterus. Pedunculated fibroids can sometimes lead to significant pain as they can twist and interrupt blood flow to the growth.

Industry Analysis

According to a new study by Polaris Market Research & Consulting, Inc. Market Research and Consulting, the uterine fibroid treatment market size was USD 4.46 billion in 2022 and is expected to grow to USD 10.83 billion at a CAGR of 9.3% during the forecast period.

The market is primarily driven by significant developments in uterine fibroids treatments. For instance, in June 2022, two new oral GnRH antagonists – Yselty & Myfembree – received approval from the #EMA and FDA . These oral antagonists, along with add-back therapy, have proven to be highly effective in reducing symptoms associated with uterine fibroids. This has led to increased demand for these treatments and is propelling the market forward.

Request Sample Copy of Research Report: https://tinyurl.com/4jzvjnd2

Symptoms Associated with Uterine Fibroids

The most common signs and symptoms of uterine fibroids are:

·???????Heavy or excessive bleeding during the menstrual cycle

·???????Periods lasting more than a week

·???????Pressure or pain in the pelvic area

·???????Urge to urinate frequently

·???????Pain in the lower back

·???????Constipation

·???????Inability to empty the bladder

The GnRH Antagonists Segment is Anticipated to Garner a Significant Growth Rate

The Gonadotropin-releasing Hormone (#GnRH) agonists segment is forecasted to grow significantly in the upcoming years. The segment’s growth is primarily driven by the increasing usage of GnRH antagonists in uterine fibroid treatments. Besides, GnRH antagonists' demonstrated efficacy and safety are impacting the segment’s growth favorably.

Browse Detail Report with TOC: https://tinyurl.com/bdydcz5w

Geographic Analysis

North America: North America dominated the uterine fibroid treatment market in 2022. This is primarily due to the presence of favorable reimbursement policies and well-established healthcare infrastructure. Besides, a significant number of market key players are operating in the region, further fueling its growth.

Asia Pacific: Asia Pacific is projected to grow with a healthy CAGR over the forecast period. Rising adoption of minimally invasive surgical procedures and increasing awareness about the availability of innovative treatment methods are some of the key factors fueling market sales in the region.

Future Cognizance

Uterine fibroids are non-cancerous uterine growth that can occur during childbearing years. The development of these fibroids is linked to various health risks, including reduced fertility, diabetes mellitus, and hypertension. As more and more people seek more effective treatment options for Uterine fibroids, the uterine fibroid treatment market share is forecasted to grow significantly in the near future.?